The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Dual Inhibition of the Lactate Transporters MCT1 and MCT4 Is Synthetic Lethal with Metformin due to NAD+ Depletion in Cancer Cells
Open accessAbstract
Highly glycolytic cancer cells prevent intracellular acidification by excreting the glycolytic end-products lactate and H + via the monocarboxylate transporters 1 (MCT1) and 4 (MCT4). We report that syrosingopine, an anti-hypertensive drug, is a dual MCT1 and MCT4 inhibitor (with 60-fold higher potency on MCT4) that prevents lactate and H + efflux. Syrosingopine elicits synthetic lethality with metformin, an inhibitor of mitochondrial NADH dehydrogenase. NAD+, required for the ATP-generating steps of glycolysis, is regenerated from NADH by mitochondrial NADH dehydrogenase or lactate dehydrogenase. Syrosingopine treatment leads to high intracellular lactate levels and thereby end-product inhibition of lactate dehydrogenase. The loss of NAD+ regeneration capacity due to combined metformin and syrosingopine treatment results in glycolytic blockade, leading to ATP depletion and cell death. Accordingly, ATP levels can be partly restored by exogenously provided NAD+, the NAD precursor nicotinamide mononucleotide (NMN), or vitamin K2. Thus, pharmacological inhibition of MCT1 and MCT4 combined with metformin treatment is a potential cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
LDHA-Associated Lactic Acid Production Blunts Tumor Immunosurveillance by T and NK Cells
Brand, A., Singer, K., Koehl, G. E., Kolitzus, M., Schoenhammer, G., Thiel, A., Matos, C., Bruss, C., Klobuch, S., Peter, K., et al. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.08.011 · Cited by 2,039
Inhibitory effect of tumor cell-derived lactic acid on human T cells
Fischer, K., Hoffmann, P., Voelkl, S., Meidenbauer, N., Ammer, J., Edinger, M., Gottfried, E., Schwarz, S., Rothe, G., Hoves, S., et al. (2007) · Blood · doi:10.1182/blood-2006-07-035972 · Cited by 1,946
Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice
Sonveaux, P., Végran, F., Schroeder, T., Wergin, M. C., Verrax, J., Rabbani, Z. N., De Saedeleer, C. J., Kennedy, K. M., Diepart, C., Jordan, B. F., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci36843 · Cited by 1,624
The reverse Warburg effect: Aerobic glycolysis in cancer associated fibroblasts and the tumor stroma
Pavlides, S., Whitaker-Menezes, D., Castello-Cros, R., Flomenberg, N., Witkiewicz, A. K., Frank, P. G., Casimiro, M. C., Wang, C., Fortina, P., Addya, S., et al. (2009) · Cell Cycle · doi:10.4161/cc.8.23.10238 · Cited by 1,391
Lactate Metabolism in Human Lung Tumors
Faubert, B., Li, K. Y., Cai, L., Hensley, C. T., Kim, J., Zacharias, L. G., Yang, C., Do, Q. N., Doucette, S., Burguete, D., et al. (2017) · Cell · doi:10.1016/j.cell.2017.09.019 · Cited by 1,343
Acidic extracellular microenvironment and cancer
Kato, Y., Ozawa, S., Miyamoto, C., Maehata, Y., Suzuki, A., Maeda, T., & Baba, Y. (2013) · Cancer Cell International · doi:10.1186/1475-2867-13-89 · Cited by 1,300
Targeting lactate metabolism for cancer therapeutics
Doherty, J. R., & Cleveland, J. L. (2013) · Journal of Clinical Investigation · doi:10.1172/jci69741 · Cited by 1,166
Target identification using drug affinity responsive target stability (DARTS)
Lomenick, B., Hao, R., Jonai, N., Chin, R. M., Aghajan, M., Warburton, S., Wang, J., Wu, R. P., Gomez, F., Loo, J. A., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0910040106 · Cited by 1,095
NAD+ Intermediates: The Biology and Therapeutic Potential of NMN and NR
Yoshino, J., Baur, J. A., & Imai, S.-I. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2017.11.002 · Cited by 1,061
Ullah, M. S., Davies, A. J., & Halestrap, A. P. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m511397200 · Cited by 890
The SLC16 gene family – Structure, role and regulation in health and disease
Halestrap, A. P. (2013) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2012.05.003 · Cited by 763
Kirk, P., Wilson, M. C., Heddle, C., Brown, M. H., Barclay, A. N., & Halestrap, A. P. (2000) · The EMBO Journal · doi:10.1093/emboj/19.15.3896 · Cited by 700
Effect of pH on the Kinetics of Frog Muscle Phosphofructokinase
Trivedi, B., & Danforth, W. H. (1966) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)99819-4 · Cited by 669
The Warburg effect: 80 years on
Potter, M., Newport, E., & Morten, K. J. (2016) · Biochemical Society Transactions · doi:10.1042/bst20160094 · Cited by 499
Le Floch, R., Chiche, J., Marchiq, I., Naiken, T., Ilc, K., Murray, C. M., Critchlow, S. E., Roux, D., Simon, M.-P., & Pouysségur, J. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1106123108 · Cited by 429
Activity of the Monocarboxylate Transporter 1 Inhibitor AZD3965 in Small Cell Lung Cancer
Polański, R., Hodgkinson, C. L., Fusi, A., Nonaka, D., Priest, L., Kelly, P., Trapani, F., Bishop, P. W., White, A., Critchlow, S. E., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2270 · Cited by 378
Kordes, S., Pollak, M. N., Zwinderman, A. H., Mathôt, R. A., Weterman, M. J., Beeker, A., Punt, C. J., Richel, D. J., & Wilmink, J. W. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00027-3 · Cited by 361
Gui, D. Y., Sullivan, L. B., Luengo, A., Hosios, A. M., Bush, L. N., Gitego, N., Davidson, S. M., Freinkman, E., Thomas, C. J., & Vander Heiden, M. G. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.09.006 · Cited by 323
Hypoxia, cancer metabolism and the therapeutic benefit of targeting lactate/H(+) symporters
Marchiq, I., & Pouysségur, J. (2016) · Journal of Molecular Medicine · doi:10.1007/s00109-015-1307-x · Cited by 300
NAD+ as a metabolic link between DNA damage and cell death
Ying, W., Alano, C. C., Garnier, P., & Swanson, R. A. (2005) · Journal of Neuroscience Research · doi:10.1002/jnr.20289 · Cited by 268
Ovens, M. J., Davies, A. J., Wilson, M. C., Murray, C. M., & Halestrap, A. P. (2010) · Biochemical Journal · doi:10.1042/bj20091515 · Cited by 260
The protein histidine phosphatase LHPP is a tumour suppressor
Hindupur, S. K., Colombi, M., Fuhs, S. R., Matter, M. S., Guri, Y., Adam, K., Cornu, M., Piscuoglio, S., Ng, C. K. Y., Betz, C., et al. (2018) · Nature · doi:10.1038/nature26140 · Cited by 243
Self-citationAllen, E., Miéville, P., Warren, C. M., Saghafinia, S., Li, L., Peng, M.-W., & Hanahan, D. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.04.029 · Cited by 221 · cited 2×
“In solid tumors, zonation of oxygen availability gives rise to tumor symbiosis where lactate excreted by a hypoxic inner core is taken up and used by tumor cells at the vascularized tumor periphery (Allen et al., 2016; Jiménez-Valerio et al., 2016; Pisarsky et al., 2016).”
BackgroundBaek, G., Tse, Y. F., Hu, Z., Cox, D., Buboltz, N., McCue, P., Yeo, C. J., White, M. A., DeBerardinis, R. J., Knudsen, E. S., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.11.025 · Cited by 219
Targeting Metabolic Symbiosis to Overcome Resistance to Anti-angiogenic Therapy
Pisarsky, L., Bill, R., Fagiani, E., Dimeloe, S., Goosen, R. W., Hagmann, J., Hess, C., & Christofori, G. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.04.028 · Cited by 197
Tsilidis, K. K., Capothanassi, D., Allen, N. E., Rizos, E. C., Lopez, D. S., van Veldhoven, K., Sacerdote, C., Ashby, D., Vineis, P., Tzoulaki, I., et al. (2014) · Diabetes Care · doi:10.2337/dc14-0584 · Cited by 190
Are Metformin Doses Used in Murine Cancer Models Clinically Relevant
Chandel, N. S., Avizonis, D., Reczek, C. R., Weinberg, S. E., Menz, S., Neuhaus, R., Christian, S., Haegebarth, A., Algire, C., & Pollak, M. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.03.010 · Cited by 176 · cited 2×
“The potential of metformin as an anti-cancer therapy may be hampered by inadequate dosing in clinical settings (Chandel et al., 2016; Dowling et al., 2016; Kordes et al., 2015).”
BackgroundMarchiq, I., Le Floch, R., Roux, D., Simon, M.-P., & Pouyssegur, J. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2260 · Cited by 175
STAMBAUGH, R. L., & Post, D. (1966) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)96733-5 · Cited by 154
Synergistic Anti-Cancer Effect of Phenformin and Oxamate
Miskimins, W. K., Ahn, H. J., Kim, J. Y., Ryu, S., Jung, Y., & Choi, J. Y. (2014) · PLoS ONE · doi:10.1371/journal.pone.0085576 · Cited by 152
Jiménez-Valerio, G., Martínez‐Lozano, M., Bassani, N., Vidal, A., Ochoa-de-Olza, M., Suárez, C., del Muro, X. G., Carles, J., Viñals, F., Graupera, M., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.04.015 · Cited by 120
Metformin Pharmacokinetics in Mouse Tumors: Implications for Human Therapy
Dowling, R. J. O., Lam, S. H. L., Bassi, C., Mouaaz, S., Aman, A. M., Kiyota, T., Al‐awar, R., Goodwin, P. J., & Stambolic, V. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.03.006 · Cited by 119
Characterization of NAD Uptake in Mammalian Cells
Billington, R. A., Travelli, C., Ercolano, E., Galli, U., Roman, C. B., Grolla, A. A., Canonico, P. L., Condorelli, F., & Genazzani, A. A. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m706204200 · Cited by 98
Syrosingopine sensitizes cancer cells to killing by metformin
Benjamin, D., Colombi, M., Hindupur, S. K., Betz, C., Lane, H. A., El‐Shemerly, M., Lu, M., Quagliata, L., Terracciano, L., Moes, S., et al. (2016) · Science Advances · doi:10.1126/sciadv.1601756 · Cited by 91
Self-citationReserpine binding to a vesicular amine transporter expressed in Chinese hamster ovary fibroblasts.
Schuldiner, S., Liu, Y., & Edwards, R. H. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)54110-7 · Cited by 83
Granja, S., Marchiq, I., LeFloch, R., Moura, C. S., Baltazar, F., & Pouysségur, J. (2014) · Oncotarget · doi:10.18632/oncotarget.2862 · Cited by 64
Voss, D. M., Spina, R., Carter, D. L., Lim, K. S., Jeffery, C. J., & Bar, E. E. (2017) · Scientific Reports · doi:10.1038/s41598-017-04612-w · Cited by 58
Effect of diclofenac on SLC16A3/MCT4 by the Caco-2 cell line
Sasaki, S., Futagi, Y., Ideno, M., Kobayashi, M., Narumi, K., Furugen, A., & Iseki, K. (2016) · Drug Metabolism and Pharmacokinetics · doi:10.1016/j.dmpk.2016.03.004 · Cited by 50
Cited by
Lactate metabolism in human health and disease
Li, X., Yang, Y., Zhang, B., Lin, X., Fu, X., An, Y., Zou, Y., Wang, J.-X., Wang, Z., & Yu, T. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01151-3 · Cited by 1,454
Lactate in the Regulation of Tumor Microenvironment and Therapeutic Approaches
de la Cruz-López, K. G., Castro-Muñoz, L. J., Reyes-Hernández, D. O., García-Carrancá, A., & Manzo-Merino, J. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01143 · Cited by 940
The anti-cancer effect of quercetin: molecular implications in cancer metabolism
Reyes-Farias, M., & Carrasco-Pozo, C. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20133177 · Cited by 689
“These transporters excrete the glycolytic end-products, lactate and H+, and prevent the intracellular acidification-induced cell death of highly glycolytic cancer cells [96].”
BackgroundCancer Metabolism: Phenotype, Signaling and Therapeutic Targets
Park, J. H., Pyun, W. Y., & Park, H. W. (2020) · Cells · doi:10.3390/cells9102308 · Cited by 548
Brown, T. P., & Ganapathy, V. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107451 · Cited by 481
Metadata
- Authors
- Benjamin, D., Robay, D., Hindupur, S. K., Pohlmann, J., Colombi, M., El-Shemerly, M. Y., Maira, S.-M., Moroni, C., Lane, H. A., & Hall, M. N.
- Venue
- Cell Reports
- Publisher
- Elsevier BV
- Published
- 2018-12
- Volume
- 25
- Issue
- 11
- Pages
- 3047-3058.e4
- ISSN
- 2211-1247 (ISSN-L)
- OpenAlex
- W2905085764
- Cited by
- 401
- References
- 38
- FWCI
- 7.65
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.